Functional assessments in repeat-dose toxicity studies: the art of the possible
Abstract
Clinical and nonclinical safety liabilities remain a major cause of adverse
Maintenance work is planned for Wednesday 1st May 2024 from 9:00am to 11:00am (BST).
During this time, the performance of our website may be affected - searches may run slowly and some pages may be temporarily unavailable. If this happens, please try refreshing your web browser or try waiting two to three minutes before trying again.
We apologise for any inconvenience this might cause and thank you for your patience.
* Corresponding authors
a
Global Safety Assessment, AstraZeneca R&D, Alderley Park, Cheshire SK10 4TG, United Kingdom
E-mail:
will.redfern@astrazeneca.com
Clinical and nonclinical safety liabilities remain a major cause of adverse
Fetching data from CrossRef.
This may take some time to load.
Loading related content